Dimebon became the clear Alzheimer front-runner at ICAD after they showed effectiveness in trials not run by sketchy Russians. Good for them, although it seems that Dimebon is just a general cognitive enhancer, similar to Aricept and friends, rather than something that attacks a specific disease process.
Dew what I find unusual is that Pfizer could have bought the whole company for not much more. I think MDVN's cap was in the $700 million range recently.
Market Data 
Markets 
AI
